Hepatitis B viral HBx induces matrix metalloproteinase‐9 gene expression through activation of ERKs and PI‐3K/AKT pathways: Involvement of invasive potential

Wiley - Tập 18 Số 10 - Trang 1123-1125 - 2004
Tae‐Wook Chung1, Young‐Choon Lee2, Cheorl‐Ho Kim1
1National Research Laboratories for Glycobiology, MOST and Department of Biochemistry and Molecular BiologyCollege of Oriental MedicineDongguk UniversityKyungju780‐714South Korea
2Faculty of BiotechnologyDong‐A UniversityBusan604‐714South Korea

Tóm tắt

ABSTRACTHepatitis B virus (HBV) X protein (HBx) has been shown to be essential for the development of hepatocellular carcinoma (HCC). Recently, we have found that HBx causes the progression of liver cancer through down‐expression of PTEN, known as a tumor suppressor gene (1). The prognosis for HCC depends mainly on the clinicopathological characteristic regarding invasion and metastasis. The expression of matrix metalloproteinase (MMP)‐9 has been implicated as playing an important role in HCC invasion and metastasis. We previously reported that HBV infection increased the invasiveness of hepatocytes and HCC cells through the transcriptional activation of MMP‐9 (2). The HBx was shown to activate the mitogen‐activated protein (MAP) kinase and phosphatidylinositol 3‐kinase (PI‐3K) signal cascade, which is essential for activation of transcription factors such as activating protein (AP)‐1 and nuclear factor (NF)‐κB. In this study, we show that the HBx protein stimulates the activities of the PI‐3K‐Akt/ protein kinase B (PKB) as well as extracellular signal‐regulated kinase 1/2 (ERK 1/2) in HBx‐transfected cells. Furthermore, we have shown that enhanced expression of MMP‐9 in HBx‐transfected cells mediated by not only activation of AP‐1 transcriptional activity through ERKs pathway but also activation of NF‐κB transcriptional activity through PI‐3K‐AKT/PKB pathway, and was associated with the invasive potential. However, treatment with U0126 (known as the ERKs inhibitor) or wortmannin (known as the PI‐3K inhibitor), but not SB203580 (known as the p38 MAPK inhibitor), markedly inhibited the expression of MMP‐9 induced by HBx in HBx‐ transfected cells. Seemingly, the invasiveness of HBx‐transfected cells was decreased by treating with U0126 or wortmannin, but not SB203580. These results clearly suggest that the HBx contributed to the transcriptional regulation of MMP‐9 through the ERKs and PI‐3K‐AKT/PKB pathway, and increased an invasive potential of cells.

Từ khóa


Tài liệu tham khảo

Chung T. W., 2003, Hepatitis B virus X protein (HBx) modulates the expression of PTEN by inhibiting the function of p53, a transcriptional activator in liver cells, Cancer Res., 63, 3453

10.1016/S0003-9861(02)00522-2

10.1126/science.6264599

10.1128/jvi.63.9.4019-4026.1989

10.1038/351317a0

10.1073/pnas.91.6.2230

Kekule’ A., 1993, Hepatitis B virus transactivador HBx uses a tumour promoter signaling pathway, Nature, 361, 742, 10.1038/361742a0

10.1126/science.1827531

10.1172/JCI118427

10.1073/pnas.91.22.10350

10.1128/jvi.70.8.4978-4985.1996

10.1128/MCB.17.11.6427

10.1074/jbc.M011263200

10.1074/jbc.273.39.25510

10.1096/fasebj.5.8.1850705

10.1016/0955-0674(93)90040-W

10.1016/0168-9525(90)90126-Q

10.1007/BF00690603

Levy A. T., 1991, Increased expression of the 72 kDa type IV collagenase in human colonic adenocarcinoma, Cancer Res., 51, 439

10.1083/jcb.113.2.437

Lengyel E., 1995, Induction of M(r) 92,000 type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts, Cancer Res., 55, 963

10.1242/jcs.104.4.991

10.1002/hep.510240206

10.1002/hep.510240513

Sato H., 1993, Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells, Oncogene, 8, 395

10.1038/sj.onc.1200973

10.4049/jimmunol.165.10.5788

10.1053/jhep.2002.32676

10.1096/fj.01-0198com

Sato T., 2002, Inhibition of activator protein‐1 binding activity and phosphatidylinositol 3‐kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases‐1 production and suppression of production of matrix metalloproteinases‐1 and ‐9 in human fibrosarcoma HT‐1080 cells, Cancer Res., 62, 1025

Genersch E., 2000, Sustained ERK phosphorylation is necessary but not sufficient for MMP‐9 regulation in endothelial cells: involvement of Ras‐dependent and ‐independent pathways, J. Cell Sci., 23, 4319, 10.1242/jcs.113.23.4319

10.1074/jbc.270.28.16483

10.1161/01.ATV.0000037679.60584.3F

10.1074/jbc.M007806200

10.1074/jbc.272.46.29167

10.1007/s002800051097

10.1111/j.1699-0463.1999.tb01535.x

10.1056/NEJM199512283332608

10.1016/S0945-053X(97)90028-7

10.1200/JCO.2000.18.5.1135

10.1152/physrev.1993.73.1.161

Garbisa S., 1987, Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c‐Ha‐ras but not c‐Ha‐ras + Ad2‐E1a, Cancer Res., 47, 1523

Bernhard E. J., 1990, Mr 92,000 gelatinase correlates with the metastatic phenotype in transformed rat embryo cells, Cancer Res., 50, 3872

10.1073/pnas.91.10.4293

Montgomery A. M., 1993, Melanoma‐mediated dissolution of extracellular matrix: contribution of urokinase‐ dependent and metalloproteinase‐dependent proteolytic pathways, Cancer Res., 53, 693

Kohn E. C., 1995, Molecular insights into cancer invasion: strategies for prevention and intervention, Cancer Res., 55, 1856

Rao J. S., 1993, Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors, Cancer Res., 53, 2208

10.1007/BF00157681

10.1054/bjoc.2001.1810

Sakamoto Y., 2000, Overexpression of MMP‐9 correlates with growth of small hepatocellular carcinoma, Int. J. Oncol., 17, 237

Feitelson M. A., 1993, Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma, Oncogene, 8, 1109

10.1128/JVI.69.2.1107-1114.1995

10.1074/jbc.273.50.33327

10.1128/JVI.72.1.266-272.1998

10.1074/jbc.273.50.33347

10.1074/jbc.273.1.381

10.1074/jbc.M003578200

Natoli G., 1994, Ras‐ and Raf‐dependent activation of c‐jun transcriptional activity by the hepatitis B virus transactivator pX, Oncogene, 9, 2837

10.1128/jvi.70.1.641-646.1996

10.1006/viro.1993.1550

10.1073/pnas.94.26.14707

10.1615/CritRevEukarGeneExpr.v7.i1-2.90

10.1016/S0014-5793(98)01034-5

10.1073/pnas.88.3.966

10.1016/S0945-053X(97)90026-3

10.1016/S0021-9258(18)55326-6

10.1016/S0021-9258(19)61950-2

10.1111/j.1432-1033.1993.tb18359.x

Thông tin
Thông tin xuất bản

Wiley

Tập 18 Số 10

1123-1125

Thông tin tác giả